Extraintestinal manifestations of inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 2, 2008, Pages 124-133

  Jose, Folashade A ^a   Heyman, Melvin B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colitis; Crohn disease; Erythema nodosum; Growth; Pediatric; Sclerosing cholangitis; Thromboses

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BEZAFIBRATE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; COLCHICINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; DAPSONE; HYDROCHLOROTHIAZIDE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; POTASSIUM IODIDE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; AMYLOIDOSIS; ANEMIA; APHTHOUS STOMATITIS; ARTHRITIS; ARTHROPATHY; BLOOD TRANSFUSION; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CHOLELITHIASIS; COLON RESECTION; CROHN DISEASE; DRUG MEGADOSE; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; EYE DISEASE; GALLSTONE; GENETIC ASSOCIATION; GLAUCOMA; GLOMERULONEPHRITIS; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; INTESTINE FLORA; INTRAOCULAR PRESSURE; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY SURGERY; LEUKOCYTOSIS; LITHOTRIPSY; LIVER GRAFT; LOW DRUG DOSE; LUNG DISEASE; MUSCULOSKELETAL DISEASE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE UROPATHY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PATHOGENESIS; PERICARDITIS; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PLEURISY; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; PYOSTOMATITIS VEGETANS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN DISEASE; SPONDYLOARTHROPATHY; STENT; STOMATITIS; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; ULCERATIVE COLITIS; URINARY TRACT FISTULA; URINARY TRACT SURGERY; UVEITIS;

CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; ENDOCRINE SYSTEM DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LUNG DISEASES; MUSCULAR DISEASES; NERVOUS SYSTEM DISEASES; SKIN DISEASES;

EID: 38549138461     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318093f4b0     Document Type: Review

References (93)

1. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96:1116-22.
2. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003;9:2300-7.
3. Mendoza JL, Lana R, Taxonera C, et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005;125:297-300.
4. Repiso A, Alcantara M, Munoz-Rosas C, et al. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-7.
5. Grossman BJ, DeBenedetti CD. Extraintestinal manifestations of chronic inflammatory bowel disease in children. Proc Inst Med Chic 1970;28:119.
6. Stawarski A, Iwanczak B, Krzesiek E, et al. Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease. Pol Merkur Lekarski 2006;20:22-5.
7. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
8. Snook JA, de Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med 1989;72:835-40.
9. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945-53.
10. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012-23.
11. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112:1845-53.
12. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002;123:714-8.
13. Lindgren A, Wallerstedt S, Olsson R. Prevalence of Crohn's disease and simultaneous occurrence of extraintestinal complications and cancer. An epidemiologic study in adults. Scand J Gastroenterol 1996;31:74-8.
14. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985;80:615-20.
15. Monsen U, Sorstad J, Hellers G, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711-6.
16. Gellert A, Green ES, Beck ER, et al. Erythema nodosum progressing to pyoderma gangrenosum as a complication of Crohn's disease. Postgrad Med J 1983;59:791-3.
17. Powell RJ, Holbrook MR, Stevens A. Pyoderma gangrenosum and its treatment. Lancet 1997;350:1720-1.
18. Barrie A, Plevy S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin North Am 2006;35:883-93.
19. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003;37:150-4.
20. Yu JT, Chong LY, Lee KC. Metastatic Crohn's disease in a Chinese girl. Hong Kong Med J 2006;12:467-9.
21. Ytting H, Vind I, Bang D, et al. Sweet's syndrome - an extra-intestinal manifestation in inflammatory bowel disease. Digestion 2005;72:195-200.
22. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-8.
23. Banet DE, McClave SA, Callen JP. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. J Rheumatol 1994;21:1766-8.
24. Kemmett D, Hunter JA. Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol 1990;23:503-7.
25. Buahene K, Hudson M, Mowat A, et al. Erythema elevatum diutinum - an unusual association with ulcerative colitis. Clin Exp Dermatol 1991;16:204-6.
26. Elsner J, Kiehl P, Kapp A, et al. Erythema elevatum and diutinum in Crohn disease. Hautarzt 1996;47:701-4.
27. Rankin GB. Extraintestinal and systemic manifestations of inflammatory bowel disease. Med Clin North Am 1990;74:39-50.
28. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34.
29. Caspi RR, Stiff LR, Morawetz R, et al. Cytokine-dependent modulation of oral tolerance in a murine model of autoimmune uveitis. Ann N Y Acad Sci 1996;778:315-24.
30. Yang P, de Vos AF, Kijlstra A. Macrophages and MHC class II positive cells in the choroid during endotoxin induced uveitis. Br J Ophthalmol 1997;81:396-401.
31. Tripathi RC, Kirschner BS, Kipp M, et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992;102:1957-61.
32. Protzer U, Duchmann R, Hohler T, et al. Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association. Med Klin (Munich) 1996;91:330-5.
33. Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986;31:492-7.
34. Nunez C, Alecsandru DM, Mendoza JL, et al. Genetic markers linked to rheumatoid arthritis are also strongly associated with articular manifestations in ulcerative colitis patients. Hum Immunol 2006;67:324-30.
35. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92:1S-4S.
36. Keyser FD, Mielants H, Veys EM. Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2001;2:85-93.
37. Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr Opin Gastroenterol 2002;18:428-34.
38. Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
39. Szumera M, Landowski P, Kaminska B, et al. Bone mineral density in inflammatory bowel diseases in children. Med Wieku Rozwoj 2006;10:445-51.
40. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006;43:42-51.
41. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med 2004;95:469-80.
42. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399-411.
43. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
44. Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989;96:62-7.
45. Marmor L. Unicompartmental arthroplasty for osteonecrosis of the knee joint. Clin Orthop Relat Res 1993;294:247-53.
46. Ficarra G, Cicchi P, Amorosi A, et al. Oral Crohn's disease and pyostomatitis vegetans. An unusual association. Oral Surg Oral Med Oral Pathol 1993;75:220-4.
47. Philpot HC, Elewski BE, Banwell JG, et al. Pyostomatitis vegetans and primary sclerosing cholangitis: markers of inflammatory bowel disease. Gastroenterology 1992;103:668-74.
48. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102:581-7.
49. Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2001;3:477-83.
50. Rasmussen HH, Fallingborg J, Mortensen PB, et al. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol 1992;27:732-6.
51. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991;100:1319-23.
52. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385-91.
53. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-5.
54. Ponsioen CY, Lam K, van Milligen de Wit AW, et al. Four years experiencewith short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:2403-7.
55. Liden H, Norrby J, Gabel M, et al. Outcome after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2001;33:2452-3.
56. Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998;27:580-3.
57. Canbay A, Bechmann LP, Best J, et al. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol 2006;44:245-8.
58. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003;36:417-20.
59. Riegler G, D'Inca R, Sturniolo GC. et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998; 33:93-98.
60. Parente F, Pastore L, Bargiggia S. et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267-74.
61. Brink MA, Slors JF, Keulemans YC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 1999;116:1420-7.
62. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993;105:681-91.
63. Heyman MB, Wojcicki J, Kaplan S. Growth hormone in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:556-7.
64. Singh Ranger G, Lamparelli MJ, Aldridge A, et al. Surgery results in significant improvement in growth in children with Crohn's disease refractory to medical therapy. Pediatr Surg Int 2006;22:347-52.
65. Stein RB, Lichtenstein GR. Medical therapy for Crohn's disease: the state of the art. Surg Clin North Am 2001;81:71-101.
66. Wilcox GM, Aretz HT, Roy MA, et al. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 1990;98:786-91.
67. Gitkind MJ, Wright SC. Amyloidosis complicating inflammatory bowel disease. A case report and review of the literature. Dig Dis Sci 1990;35:906-8.
68. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992;71:261-70.
69. Lovat LB, Madhoo S, Pepys MB, et al. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997;112:1362-5.
70. Le Large-Guiheneuf C, Hugot JP, Faure C, et al. Pancreatic involvement in inflammatory bowel diseases in children. Arch Pediatr 2002;9:469-77.
71. Stawarski A, Iwanczak F. Incidence of acute pancreatitis in children with inflammatory bowel disease. Pol Merkur Lekarski 2004;17:33-6.
72. Stocker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1987;139:41-52.
73. Paradis K, Bernstein ML, Adelson JW. Thrombosis as a complication of inflammatory bowel disease in children: a report of four cases. J Pediatr Gastroenterol Nutr 1985;4:659-62.
74. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
75. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-56.
76. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-42.
77. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.
78. Frid C, Bjarke B, Eriksson M. Myocarditis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1986;5:964-5.
79. Patwardhan RV, Heilpern RJ, Brewster AC, et al. Pleuropericarditis: an extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med 1983;143:94-6.
80. Agnholt J, Sorensen HT, Rasmussen SN, et al. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989;1:1135.
81. Gujral N, Friedenberg F, Friedenberg J, et al. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996;41:624-6.
82. Sullivan SN. Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. J Clin Gastroenterol 1987;9:461-3.
83. Hefter H, Piontek M, Aulich A. Bacterial meningitis and dorsal spinal epidural abscess caused by Crohn's disease. Neurology 1991;41:606-8.
84. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88:681-4.
85. Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:512-7.
86. Al-Ratrout JT, Ansari NA. Epidermolysis bullosa acquisita and Crohn's disease. Saudi Med J 2004;25:1736-8.
87. Gluck M, Kayne A. Acquired epidermolysis bullosa and Crohn's disease. Gastrointest Endosc 2003;57:563-4.
88. Benton EC, Rutherford D, Hunter JA. Sweet's syndrome and pyoderma gangrenosum associated with ulcerative colitis. Acta Derm Venereol 1985;65:77-80.
89. Muller L, Bala G, Kuczynska R, et al. Pyoderma gangrenosum, a nonintestinal manifestation of Lesniowski-Crohn's disease in a 15 years old girl. Med Wieku Rozwoj 2006;10:463-73.
90. Clark JH, Fitzgerald JF, Bergstein JM. Nephrolithiasis in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1985;4:829-34.
91. Kahn E, Markowitz J, Simpser E, et al. Amyloidosis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1989;8:447-53.
92. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40.
93. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006;130:1069-77.